ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs being studied to potentially treat AD itself, versus treating its symptoms.
The Phase I clinical trial is a randomized, placebo-controlled study to determine the maximum tolerated single dose, safety, pharmacokinetics, pharmacodynamics of the drug.
Phase I clinical trial is being conducted in Germany in collaboration with ABX-CRO, which has conducted several AD studies at the University of Dresden.
Anavex Clinical Development and Medical Affairs VP Angelos Stergiou said based on several preclinical animal studies, they believe ANAVEX 2-73 is a new anti-Alzheimer’s compound that has the potential to directly address the pathology of AD, potentially halting or even reversing its course.
Dosing of at least 16 healthy volunteers is expected to be complete in approximately three months.